Please login to the form below

Not currently logged in
Email:
Password:

Scientific changes mind on endosurgery unit sale

US medical device manufacturer Boston Scientific has changed its mind over the sale of a minority stake in its endosurgery unit, due to a downturn in its main markets of stents and defibrillators.

US medical device manufacturer Boston Scientific has changed its mind over the sale of a minority stake in its endosurgery unit, due to a downturn in its main markets of stents and defibrillators.

Boston had hoped to raise around USD 1bn from the sale, which would have helped it pay off debt from the USD 27bn acquisition of Guidant in 2006. The company added that it planned to reduce costs through job cuts, sales of assets and parts of its investment portfolio.

The Guidant acquisition and other debt (USD 7bn) incurred by downturns in two of its most important medical device markets have seen Boston's stock drop. The stent market in particular has suffered due to thrombosis safety concerns over drug-eluting versions. As a result, analysts downgraded the companyπs credit ratings in July 2007.

Boston says its endosurgery unit has exhibited strong growth and should generate USD 1.4bn in revenue for FY07, which is almost 20 per cent of the company's total revenue.

In March 2007, Boston was considering an IPO of around 25 per cent of the endosurgery group, which develops devices to treat digestive, urological and gynecological disorders, as well as some cancers.

CEO James Tobin led the endosurgery sale turnaround adding that the company would benefit from keeping the unit under 100 per cent ownership.

Boston's shares fell USD 0.12 rest at USD 13.31 in after-hours trading on 2 August after rising USD 0.24 to USD 13.43 in the regular session.

3rd August 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
ROAD

ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics